{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:09:50Z","timestamp":1784020190359,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,10]]},"group-title":"Cancer Biology","reference-count":53,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS-alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms between\n                  <jats:italic>KRAS<\/jats:italic>\n                  G12D and\n                  <jats:italic>KRAS<\/jats:italic>\n                  G12R, alleles with fundamentally different RAS network dynamics. Daraxonrasib inhibited KRAS\n                  <jats:sup>MUT<\/jats:sup>\n                  primarily through steric occlusion of effector binding, while engaging RAS\n                  <jats:sup>WT<\/jats:sup>\n                  only modestly (\u223c20%). KRAS\n                  <jats:sup>G12R<\/jats:sup>\n                  is marked by its inability to transactivate RAS\n                  <jats:sup>WT<\/jats:sup>\n                  , and it was observed that daraxonrasib resistant KRAS\n                  <jats:sup>G12R<\/jats:sup>\n                  PDAC cells utilize EGFR\/RAS\n                  <jats:sup>WT<\/jats:sup>\n                  -GTP signaling as the dominant adaptive route. In contrast, KRAS\n                  <jats:sup>G12D<\/jats:sup>\n                  resistance arose through retained KRAS\n                  <jats:sup>G12D<\/jats:sup>\n                  -GTP signaling, with a decrease of cyclophilin A (CypA) protein, the binding partner required for daraxonrasib activity. The shift from KRAS\n                  <jats:sup>G12R<\/jats:sup>\n                  dependence to the EGFR\/RAS\n                  <jats:sup>WT<\/jats:sup>\n                  conferred sensitivity to trametinib. We confirmed this clinically: a KRAS\n                  <jats:sup>G12R<\/jats:sup>\n                  PDAC patient who progressed after 10 months on daraxonrasib showed intratumoral EGFR\/RAS\n                  <jats:sup>WT<\/jats:sup>\n                  activation, and rapid 3D-bioprinted patient-derived toroid modeling predicted sensitivity to trametinib-based combination therapy. Given the aggressive disease trajectory and lack of response to the two immediately preceding lines of therapy, sixth-line trametinib-based combination therapy achieved approximately 5 months of disease control. This patient ultimately achieved 40 months of overall survival, far exceeding the 8\u201312 month median for metastatic PDAC. Collectively, these data establish a framework in which allele-specific RAS network topology dictates the adaptive resistance landscape, enabling rational selection of targeted therapies with meaningful clinical benefit in metastatic PDAC.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>STATEMENT OF SIGNIFICANCE<\/jats:title>\n                  <jats:p>\n                    Daraxonrasib resistance mechanisms have allele-specific routes: CypA becomes downregulated in KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    and reliance on EGFR\/RAS\n                    <jats:sup>WT<\/jats:sup>\n                    in KRAS\n                    <jats:sup>G12R<\/jats:sup>\n                    . Rapid patient-derived toroids identified sixth-line targeted therapy strategies with an overall survival of 40 months.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.07.05.735339","type":"posted-content","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:15:11Z","timestamp":1783721711000},"source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer"],"prefix":"10.64898","author":[{"given":"Daniel","family":"Dorbin","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliannie","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raven","family":"Davidson","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen Kumar","family":"Chandrashekar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Scheuber","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanga","family":"Jayakrishnan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabelle","family":"Rajesh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC"},{"name":"Hollings Cancer Center.Thomas Jefferson University, Philadelphia, PA, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayson","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC"},{"name":"Hollings Cancer Center.Thomas Jefferson University, Philadelphia, PA, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sochor","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Langenheim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology, and Cancer Biology, Medical University of South Carolina, Charleston, SC"},{"name":"Sidney Kimmel Comprehensive Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Messerly","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[{"name":"Data Science Institute, Division of Biostatistics, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forough Azam","family":"Sayahpour","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L.","family":"Atallah","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis C.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Volkman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Department of Surgery. Medical College of Wisconsin, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Surgery. Medical College of Wisconsin, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki K.","family":"Lytle","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. David","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Aaron","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC"},{"name":"Hollings Cancer Center.Thomas Jefferson University, Philadelphia, PA, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McFall","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"},{"name":"Cancer Center, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026071402000503000_2026.07.05.735339v1.1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","year":"2024","journal-title":"Npj Precis Oncol"},{"key":"2026071402000503000_2026.07.05.735339v1.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0027"},{"key":"2026071402000503000_2026.07.05.735339v1.3","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02314"},{"key":"2026071402000503000_2026.07.05.735339v1.4","doi-asserted-by":"crossref","unstructured":"Holderfield M , Lee BJ , Jiang J , Tomlinson A , Seamon KJ , Mira A , et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024.","DOI":"10.1038\/s41586-024-07205-6"},{"key":"2026071402000503000_2026.07.05.735339v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104250"},{"key":"2026071402000503000_2026.07.05.735339v1.6","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly EM , Wainberg ZA , Hendifar AE , Borad MJ , Pietrantonio F , Pant S , et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026.","DOI":"10.1056\/NEJMoa2605555"},{"key":"2026071402000503000_2026.07.05.735339v1.7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12885-023-10917-z","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","year":"2023","journal-title":"BMC Cancer"},{"key":"2026071402000503000_2026.07.05.735339v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00301-6"},{"key":"2026071402000503000_2026.07.05.735339v1.9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","year":"2025","journal-title":"Trends Cancer"},{"key":"2026071402000503000_2026.07.05.735339v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281"},{"key":"2026071402000503000_2026.07.05.735339v1.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2077"},{"key":"2026071402000503000_2026.07.05.735339v1.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144642"},{"key":"2026071402000503000_2026.07.05.735339v1.13","doi-asserted-by":"crossref","unstructured":"Kamgar M , Hobbs GA , Davidson R , Dorbin D , Herrera J , Langenheim JF , et al. Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer Res. 2026.","DOI":"10.1158\/0008-5472.CAN-25-0018"},{"key":"2026071402000503000_2026.07.05.735339v1.14","doi-asserted-by":"crossref","first-page":"110096","DOI":"10.1016\/j.celrep.2021.110096","article-title":"Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach","volume":"37","year":"2021","journal-title":"Cell Rep"},{"key":"2026071402000503000_2026.07.05.735339v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0473-9"},{"key":"2026071402000503000_2026.07.05.735339v1.16","doi-asserted-by":"crossref","unstructured":"McFall T , Diedrich JK , Mengistu M , Littlechild SL , Paskvan KV , Sisk-Hackworth L , et al. A systems mechanism for KRAS mutant allele\u2013specific responses to targeted therapy. Sci Signal. 2019;12.","DOI":"10.1126\/scisignal.aaw8288"},{"key":"2026071402000503000_2026.07.05.735339v1.17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41698-022-00329-w","article-title":"Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP","volume":"6","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026071402000503000_2026.07.05.735339v1.18","doi-asserted-by":"crossref","unstructured":"He K , Zhang X , Ren S , Sun J. Deep residual learning for image recognition. 2016. p.770\u20138.","DOI":"10.1109\/CVPR.2016.90"},{"key":"2026071402000503000_2026.07.05.735339v1.19","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0203"},{"key":"2026071402000503000_2026.07.05.735339v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.002"},{"key":"2026071402000503000_2026.07.05.735339v1.21","doi-asserted-by":"crossref","unstructured":"Burge RA , Le Roux O , Popow O , Spadafora VK , Rajesh C , Adair SJ , et al. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK\/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer Res. 2026.","DOI":"10.1158\/0008-5472.c.8542490"},{"key":"2026071402000503000_2026.07.05.735339v1.22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1006"},{"key":"2026071402000503000_2026.07.05.735339v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08283-2"},{"key":"2026071402000503000_2026.07.05.735339v1.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3210"},{"key":"2026071402000503000_2026.07.05.735339v1.25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144642"},{"key":"2026071402000503000_2026.07.05.735339v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02638-1"},{"key":"2026071402000503000_2026.07.05.735339v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142674"},{"key":"2026071402000503000_2026.07.05.735339v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3682"},{"key":"2026071402000503000_2026.07.05.735339v1.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"2026071402000503000_2026.07.05.735339v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2010.23"},{"key":"2026071402000503000_2026.07.05.735339v1.31","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/srep06468","article-title":"Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation","volume":"4","year":"2014","journal-title":"Sci Rep"},{"key":"2026071402000503000_2026.07.05.735339v1.32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/2472555218766842","article-title":"Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening","volume":"23","year":"2018","journal-title":"SLAS Discov"},{"key":"2026071402000503000_2026.07.05.735339v1.33","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/nprot.2013.125","article-title":"Three-dimensional cell culturing by magnetic levitation","volume":"8","year":"2013","journal-title":"Nat Protoc"},{"key":"2026071402000503000_2026.07.05.735339v1.34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/2472630319854337","article-title":"Automating a magnetic 3D spheroid model technology for high-throughput screening","volume":"24","year":"2019","journal-title":"SLAS Technol"},{"key":"2026071402000503000_2026.07.05.735339v1.35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.747"},{"key":"2026071402000503000_2026.07.05.735339v1.36","first-page":"43","article-title":"MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy","volume":"10","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2026071402000503000_2026.07.05.735339v1.37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-018-3545-4","article-title":"Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model","volume":"81","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071402000503000_2026.07.05.735339v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1613-0"},{"key":"2026071402000503000_2026.07.05.735339v1.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9525"},{"key":"2026071402000503000_2026.07.05.735339v1.40","doi-asserted-by":"crossref","first-page":"a006108","DOI":"10.1101\/mcs.a006108","article-title":"Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report","volume":"7","year":"2021","journal-title":"Mol Case Stud"},{"key":"2026071402000503000_2026.07.05.735339v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0367-9"},{"key":"2026071402000503000_2026.07.05.735339v1.42","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04445"},{"key":"2026071402000503000_2026.07.05.735339v1.43","doi-asserted-by":"crossref","first-page":"e2600138","DOI":"10.1200\/PO-26-00138","article-title":"Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO","volume":"10","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"2026071402000503000_2026.07.05.735339v1.44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/0008-5472.CAN-25-1835","article-title":"CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer","volume":"86","year":"2026","journal-title":"Cancer Res"},{"key":"2026071402000503000_2026.07.05.735339v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02676-9"},{"key":"2026071402000503000_2026.07.05.735339v1.46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/mc.23908","article-title":"Differential Response and Resistance to KRAS-Targeted Therapy","volume":"64","year":"2025","journal-title":"Mol Carcinog"},{"key":"2026071402000503000_2026.07.05.735339v1.47","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31040150"},{"key":"2026071402000503000_2026.07.05.735339v1.48","doi-asserted-by":"crossref","unstructured":"Zeiser R , Andrlov\u00e1 H , Meiss F. Trametinib (GSK1120212). In: Martens UM, editor. Small Mol Oncol. Cham: Springer International Publishing; 2018. p.91\u2013100.","DOI":"10.1007\/978-3-319-91442-8_7"},{"key":"2026071402000503000_2026.07.05.735339v1.49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1006"},{"key":"2026071402000503000_2026.07.05.735339v1.50","doi-asserted-by":"crossref","unstructured":"Knox JJ , O\u2019Kane G , King D , Laheru D , Habowski AN , Yu K , et al. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine\/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. J Clin Oncol. 2025;JCO-25-00436.","DOI":"10.1200\/JCO-25-02195"},{"key":"2026071402000503000_2026.07.05.735339v1.51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-024-12016-z","article-title":"Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study","volume":"24","year":"2024","journal-title":"BMC Cancer"},{"key":"2026071402000503000_2026.07.05.735339v1.52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-024-11823-8","article-title":"Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer","volume":"24","year":"2024","journal-title":"BMC Cancer"},{"key":"2026071402000503000_2026.07.05.735339v1.53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1200\/JCO.2023.41.4_suppl.711","article-title":"Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer","volume":"41","year":"2023","journal-title":"J Clin Oncol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.05.735339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:00:18Z","timestamp":1784019618000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.05.735339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":53,"URL":"https:\/\/doi.org\/10.64898\/2026.07.05.735339","relation":{},"subject":[],"published":{"date-parts":[[2026,7,10]]},"subtype":"preprint"}}